🇺🇸 FDA

Intelligence Platform

Patents

Browse 2,828 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 10434100

Protein phosphatase 2A inhibitors for treating myelodysplastic syndromes

Lixte Biotechnology, Inc. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434096

Tyrosine kinase inhibitors

Rigel Pharmaceuticals, Inc. · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10434075

FKBP52 specific androgen receptor inhibitor, MJC13, for use in treating breast cancer

The Board of Regents of the University of Texas System · Granted Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428157

Dosing regimens for use with PCSK9 inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428057

Bicyclo[1.1.1]pentane inhibitors of dual leucine zipper (DLK) kinase for the treatment of

The Board of Regents of the University of Texas System · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428050

Substituted reverse pyrimidine Bmi-1 inhibitors

PTC THERAPEUTICS, INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10428028

HDAC inhibitors

BIOMARIN PHARMACEUTICAL INC. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10426767

Methods of treating cancer with farnesyltransferase inhibitors

Kura Oncolofy, Inc. · Granted Tue Oct 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421802

Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10421765

Tetrahydropyrido[4,3-d]pyrimidine inhibitors of ATR kinase

The Board of Regents of the University of Texas System · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420813

Competitive inhibitors of invariant chain expression and/or ectopic clip binding

The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10420758

Indolinyl-sulfonamide inhibitors of tankyrase and methods of use thereof

The Board of Regents of the University of Texas System · Granted Tue Sep 24 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 19 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10416163

Method and treatment of recurring endometrial cancer with an inhibitor of USP14

Regents of the University of Minnesota · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10414740

Glutaminase inhibitors and method of use

Agios Pharmaceuticals, Inc. · Granted Tue Sep 17 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 12 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10407445

Hepatitis C virus inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10407409

6-(5-hydroxy-1H-pyrazol-1-yl)nicotinamide inhibitors of PHD

Takeda Pharmaceutical Company Limited · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10406148

Methods of treatment using a JAK inhibitor compound

Theravance Biopharma R&D IP, LLC · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400010

Structure-based peptide inhibitors of P53 aggregation as a new approach to cancer therapeu

The Regents of the University of California · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10398706

Heteroaryldiazepine derivatives as RSV inhibitors

Enanta Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392439

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392391

Compounds useful as inhibitors of ATR kinase

Vertex Pharmaceuticals Incorporated · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392386

JAK inhibitors containing a 4-membered heterocyclic amide

Theravance Biopharma R&D IP, LLC · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10392376

Heterocyclic inhibitors of ATR kinase

The Board of Regents of the University of Texas System · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391175

BET bromodomain inhibitors and therapeutic methods using the same

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted